Logo of bmjLink to Publisher's site
BMJ. 1989 Mar 11; 298(6674): 636–642.
PMCID: PMC1835889

Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial.


OBJECTIVE--To determine the efficacy of oral nimodipine in reducing cerebral infarction and poor outcomes (death and severe disability) after subarachnoid haemorrhage. DESIGN--Double blind, placebo controlled, randomised trial with three months of follow up and intention to treat analysis. To have an 80% chance with a significance level of 0.05 of detecting a 50% reduction in an incidence of cerebral infarction of 15% a minimum of 540 patients was required. SETTING--Four regional neurosurgical units in the United Kingdom. PATIENTS--In all 554 patients were recruited between June 1985 and September 1987 out of a population of 1115 patients admitted with subarachnoid haemorrhage proved by the results of lumbar puncture or computed tomography, or both. The main exclusion criterion was admission to the neurosurgical units more than 96 hours after subarachnoid haemorrhage. There were four breaks of code and no exclusions after entry. One patient was withdrawn and in 130 treatment was discontinued early. All patients were followed up for three months and were included in the analysis, except the patient who had been withdrawn. INTERVENTIONS--Placebo or nimodipine 60 mg was given orally every four hours for 21 days to 276 and 278 patients, respectively. Treatment was started within 96 hours after subarachnoid haemorrhage. END POINTS--Incidence of cerebral infarction and ischaemic neurological deficits and outcome three months after entry. MEASUREMENTS--Demographic and clinical data, including age, sex, history of hypertension and subarachnoid haemorrhage, severity of haemorrhage according to an adaptation of the Glasgow coma scale, number and site of aneurysms on angiography, and initial findings on computed tomography were measured at entry. Deterioration, defined as development of a focal sign or fall of more than one point on the Glasgow coma scale for more than six hours, was investigated by using clinical criteria and by computed tomography, by lumbar puncture, or at necropsy when appropriate. All episodes of deterioration and all patients with a three month outcome other than a good recovery were assessed by a review committee. MAIN RESULTS--Demographic and clinical data at entry were similar in the two groups. In patients given nimodipine the incidence of cerebral infarction was 22% (61/278) compared with 33% (92/276) in those given placebo, a significant reduction of 34% (95% confidence interval 13 to 50%). Poor outcomes were also significantly reduced by 40% (95% confidence interval 20 to 55%) with nimodipine (20% (55/278) in patients given nimodipine v 33% (91/278) in those given placebo). CONCLUSIONS--Oral nimodipine 60 mg four hourly is well tolerated and reduces cerebral infarction snd improves outcome after subarachnoid haemorrhage.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.6M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Allen GS, Ahn HS, Preziosi TJ, Battye R, Boone SC, Boone SC, Chou SN, Kelly DL, Weir BK, Crabbe RA, et al. Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med. 1983 Mar 17;308(11):619–624. [PubMed]
  • Symon L. Disordered cerebro-vascular physiology in aneurysmal subarachnoid haemorrhage. Acta Neurochir (Wien) 1978;41(1-3):7–22. [PubMed]
  • Pickard JD, Matheson M, Patterson J, Wyper D. Prediction of late ischemic complications after cerebral aneurysm surgery by the intraoperative measurement of cerebral blood flow. J Neurosurg. 1980 Sep;53(3):305–308. [PubMed]
  • Simeone FA, Vinall P. Mechanisms of contractile response of cerebral artery to externally-applied fresh blood. J Neurosurg. 1975 Jul;43(1):37–47. [PubMed]
  • Brandt L, Andersson KE, Edvinsson L, Ljunggren B. Effects of extracellular calcium and of calcium antagonists on the contractile responses of isolated human pial and mesenteric arteries. J Cereb Blood Flow Metab. 1981;1(3):339–347. [PubMed]
  • Kazda S, Towart R. Nimodipine: a new calcium antagonistic drug with a preferential cerebrovascular action. Acta Neurochir (Wien) 1982;63(1-4):259–265. [PubMed]
  • Harris RJ, Branston NM, Symon L, Bayhan M, Watson A. The effects of a calcium antagonist, nimodipine, upon physiological responses of the cerebral vasculature and its possible influence upon focal cerebral ischaemia. Stroke. 1982 Nov-Dec;13(6):759–766. [PubMed]
  • Grotenhuis JA, Bettag W, Fiebach BJ, Dabir K. Intracarotid slow bolus injection of nimodipine during angiography for treatment of cerebral vasospasm after SAH. A preliminary report. J Neurosurg. 1984 Aug;61(2):231–240. [PubMed]
  • Ljunggren B, Brandt L, Säveland H, Nilsson PE, Cronqvist S, Andersson KE, Vinge E. Outcome in 60 consecutive patients treated with early aneurysm operation and intravenous nimodipine. J Neurosurg. 1984 Nov;61(5):864–873. [PubMed]
  • Nosko M, Weir B, Krueger C, Cook D, Norris S, Overton T, Boisvert D. Nimodipine and chronic vasospasm in monkeys: Part 1. Clinical and radiological findings. Neurosurgery. 1985 Feb;16(2):129–136. [PubMed]
  • Philippon J, Grob R, Dagreou F, Guggiari M, Rivierez M, Viars P. Prevention of vasospasm in subarachnoid haemorrhage. A controlled study with nimodipine. Acta Neurochir (Wien) 1986;82(3-4):110–114. [PubMed]
  • Petruk KC, West M, Mohr G, Weir BK, Benoit BG, Gentili F, Disney LB, Khan MI, Grace M, Holness RO, et al. Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial. J Neurosurg. 1988 Apr;68(4):505–517. [PubMed]
  • Gotoh O, Mohamed AA, McCulloch J, Graham DI, Harper AM, Teasdale GM. Nimodipine and the haemodynamic and histopathological consequences of middle cerebral artery occlusion in the rat. J Cereb Blood Flow Metab. 1986 Jun;6(3):321–331. [PubMed]
  • Shaw MD, Foy PM, Conway M, Pickard JD, Maloney P, Spillane JA, Chadwick DW. Dipyridamole and postoperative ischemic deficits in aneurysmal subarachnoid hemorrhage. J Neurosurg. 1985 Nov;63(5):699–703. [PubMed]
  • Vermeulen M, Lindsay KW, Murray GD, Cheah F, Hijdra A, Muizelaar JP, Schannong M, Teasdale GM, van Crevel H, van Gijn J. Antifibrinolytic treatment in subarachnoid hemorrhage. N Engl J Med. 1984 Aug 16;311(7):432–437. [PubMed]
  • Mohsen F, Pomonis S, Illingworth R. Prediction of delayed cerebral ischaemia after subarachnoid haemorrhage by computed tomography. J Neurol Neurosurg Psychiatry. 1984 Nov;47(11):1197–1202. [PMC free article] [PubMed]
  • Auer LM. Acute operation and preventive nimodipine improve outcome in patients with ruptured cerebral aneurysms. Neurosurgery. 1984 Jul;15(1):57–66. [PubMed]
  • Teasdale GM, Drake CG, Hunt W, Kassell N, Sano K, Pertuiset B, De Villiers JC. A universal subarachnoid hemorrhage scale: report of a committee of the World Federation of Neurosurgical Societies. J Neurol Neurosurg Psychiatry. 1988 Nov;51(11):1457–1457. [PMC free article] [PubMed]
  • Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet. 1975 Mar 1;1(7905):480–484. [PubMed]
  • Gelmers HJ, Gorter K, de Weerdt CJ, Wiezer HJ. A controlled trial of nimodipine in acute ischemic stroke. N Engl J Med. 1988 Jan 28;318(4):203–207. [PubMed]
  • Neil-Dwyer G, Mee E, Dorrance D, Lowe D. Early intervention with nimodipine in subarachnoid haemorrhage. Eur Heart J. 1987 Nov;8 (Suppl K):41–47. [PubMed]
  • Ohman J, Heiskanen O. Effect of nimodipine on the outcome of patients after aneurysmal subarachnoid hemorrhage and surgery. J Neurosurg. 1988 Nov;69(5):683–686. [PubMed]
  • Jan M, Buchheit F, Tremoulet M. Therapeutic trial of intravenous nimodipine in patients with established cerebral vasospasm after rupture of intracranial aneurysms. Neurosurgery. 1988 Aug;23(2):154–157. [PubMed]
  • Vinge E, Andersson KE, Brandt L, Ljunggren B, Nilsson LG, Rosendal-Helgesen S. Pharmacokinetics of nimodipine in patients with aneurysmal subarachnoid haemorrhage. Eur J Clin Pharmacol. 1986;30(4):421–425. [PubMed]
  • Stullken EH, Jr, Balestrieri FJ, Prough DS, McWhorter JM. The hemodynamic effects of nimodipine in patients anesthetized for cerebral aneurysm clipping. Anesthesiology. 1985 Mar;62(3):346–348. [PubMed]
  • Merin RG. Calcium channel blocking drugs and anesthetics: is the drug interaction beneficial or detrimental? Anesthesiology. 1987 Feb;66(2):111–113. [PubMed]
  • Tettenborn D, Dycka J, Volberg E, Düdden P. Blood pressure and heart rate during treatment with nimodipine in patients with subarachnoid hemorrhage. Neurochirurgia (Stuttg) 1985 May;28 (Suppl 1):84–86. [PubMed]
  • O'Neill P, West CR, Chadwick DW, Conway M, Foy PM, Maloney P, Pickard JD, Spillane JA, Shaw MD. Post-ictal blood pressure in aneurysmal subarachnoid haemorrhage. Br J Neurosurg. 1988;2(2):153–159. [PubMed]
  • Brandt L, Ljunggren B, Andersson KE, Edvinsson L, MacKenzie E, Tamura A, Teasdale G. Effects of topical application of a calcium antagonist (nifedipine) on feline cortical pial microvasculature under normal conditions and in focal ischemia. J Cereb Blood Flow Metab. 1983 Mar;3(1):44–50. [PubMed]
  • Takayasu M, Bassett JE, Dacey RG., Jr Effects of calcium antagonists on intracerebral penetrating arterioles in rats. J Neurosurg. 1988 Jul;69(1):104–109. [PubMed]
  • Middlemiss DN, Spedding M. A functional correlate for the dihydropyridine binding site in rat brain. Nature. 1985 Mar 7;314(6006):94–96. [PubMed]
  • Pickard JD, Walker V, Vile J, Perry S, Smythe PJ, Hunt R. Oral nimodipine reduces prostaglandin and thromboxane production by arteries chronically exposed to a periarterial haematoma and the antifibrinolytic agent tranexamic acid. J Neurol Neurosurg Psychiatry. 1987 Jun;50(6):727–731. [PMC free article] [PubMed]
  • Phillis JW, O'Regan MH, Walter GA. Effects of nifedipine and felodipine on adenosine and inosine release from the hypoxemic rat cerebral cortex. J Cereb Blood Flow Metab. 1988 Apr;8(2):179–185. [PubMed]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Group


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem chemical compound records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records. Multiple substance records may contribute to the PubChem compound record.
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...